The relationship between prostate cancer outcome and AR levels in stroma and epithelium was investigated by AR immunohistochemistry on 64 patient-matched BPH and prostate cancer samples in patients of median age 87 years (Fig. 1A). This evidence concerns the gene AR and benign prostatic hyperplasia.